



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Operations Office**

---

Date: July 1, 2011

To: NCCTG Principle Investigators  
NCCTG Primary Clinical Research Associates

From: Tamra Chomjak, MBA  
Research Protocol Specialist III

Re: Requested tissue submission for N0775, A Randomized Phase II Trial of Temozolomide (TMZ) and Avastin® or ABI-007/Carboplatin (CBDCA) and Avastin® in Patients with Unresectable Stage IV Malignant Melanoma

As a result of Addendum 12 for the above listed NCCTG study and the request for optional tissue collection, we have developed 2 letters for use for contacting patients and/or patient relatives to request consent.

Please note that these letters will be distributed to the NCCTG memberships on July 1, 2011. You may download the protocol material by clicking on the link below:

[http://ncctg.mayo.edu/protocols/N0775/TissueRequestLetters\\_ProtMail\\_01Jul2011.pdf](http://ncctg.mayo.edu/protocols/N0775/TissueRequestLetters_ProtMail_01Jul2011.pdf).

If you have trouble accessing this document, please feel free to contact me.

Thank you.